Patients With Advanced Solid Tumors
8
4
4
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
12.5%
1 terminated out of 8 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
PM534 Administered Intravenously to Patients With Advanced Solid Tumors
Safety and Tolerability of Intravenous Administration of ICVB-1042
A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
BAT7104 in Patients With Advanced Solid Tumours
A Study of ICP-033 in Patients With Advanced Solid Tumors
ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy
A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
Clinical Study of JS007 in Patients With Advanced Solid Tumors